Imatinib and hypophosphatemia: Case report and review of literature
Imatinib mesylate is a potent inhibitor of the BCR-Abl kinases, c-Kit, PDGFR, and fms. Imatinib used for treatment of chronic myeloid leukemia and gastrointestinal stromal tumor. Imatinib has been well tolerated. The most common adverse events reported included edema, nausea, diarrhea, myalgia or mu...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Turkiye Klinikleri
2017-07-01
|
| Series: | Journal of Oncological Sciences |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2452336417300031 |
| id |
doaj-b8bebdaee9f94a4884c246843f7995d4 |
|---|---|
| record_format |
Article |
| spelling |
doaj-b8bebdaee9f94a4884c246843f7995d42020-11-25T01:49:11ZengTurkiye KlinikleriJournal of Oncological Sciences2452-33642017-07-0132929510.1016/j.jons.2017.05.002Imatinib and hypophosphatemia: Case report and review of literatureErdem Şenİrem ÖnerÖzlem AtaImatinib mesylate is a potent inhibitor of the BCR-Abl kinases, c-Kit, PDGFR, and fms. Imatinib used for treatment of chronic myeloid leukemia and gastrointestinal stromal tumor. Imatinib has been well tolerated. The most common adverse events reported included edema, nausea, diarrhea, myalgia or musculoskeletal pain, fatigue, dermatitis or rash, headache and abdominal pain. Hypophosphatemia is rare side effect of imatinib treatment. This is the report of a case experiencing severe hypophosphatemia during adjuvant treatment with imatinib for gastrointestinal stromal tumor.http://www.sciencedirect.com/science/article/pii/S2452336417300031ImatinibHypophosphatemiaGastrointestinal stromal tumor |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Erdem Şen İrem Öner Özlem Ata |
| spellingShingle |
Erdem Şen İrem Öner Özlem Ata Imatinib and hypophosphatemia: Case report and review of literature Journal of Oncological Sciences Imatinib Hypophosphatemia Gastrointestinal stromal tumor |
| author_facet |
Erdem Şen İrem Öner Özlem Ata |
| author_sort |
Erdem Şen |
| title |
Imatinib and hypophosphatemia: Case report and review of literature |
| title_short |
Imatinib and hypophosphatemia: Case report and review of literature |
| title_full |
Imatinib and hypophosphatemia: Case report and review of literature |
| title_fullStr |
Imatinib and hypophosphatemia: Case report and review of literature |
| title_full_unstemmed |
Imatinib and hypophosphatemia: Case report and review of literature |
| title_sort |
imatinib and hypophosphatemia: case report and review of literature |
| publisher |
Turkiye Klinikleri |
| series |
Journal of Oncological Sciences |
| issn |
2452-3364 |
| publishDate |
2017-07-01 |
| description |
Imatinib mesylate is a potent inhibitor of the BCR-Abl kinases, c-Kit, PDGFR, and fms. Imatinib used for treatment of chronic myeloid leukemia and gastrointestinal stromal tumor. Imatinib has been well tolerated. The most common adverse events reported included edema, nausea, diarrhea, myalgia or musculoskeletal pain, fatigue, dermatitis or rash, headache and abdominal pain. Hypophosphatemia is rare side effect of imatinib treatment. This is the report of a case experiencing severe hypophosphatemia during adjuvant treatment with imatinib for gastrointestinal stromal tumor. |
| topic |
Imatinib Hypophosphatemia Gastrointestinal stromal tumor |
| url |
http://www.sciencedirect.com/science/article/pii/S2452336417300031 |
| work_keys_str_mv |
AT erdemsen imatinibandhypophosphatemiacasereportandreviewofliterature AT iremoner imatinibandhypophosphatemiacasereportandreviewofliterature AT ozlemata imatinibandhypophosphatemiacasereportandreviewofliterature |
| _version_ |
1725008170952163328 |